reported the outcome of 59 HSCT recipients with GATA2 deficiency and compared transplant outcome based on GVHD prophylaxis (PT-CY vs. tacrolimus and methotrexate-based prophylaxis). The gene discussed is GATA2; the disease is graft versus host disease.